<DOC>
	<DOCNO>NCT02407366</DOCNO>
	<brief_summary>The current standard care unresectable locally advanced non-small-cell lung cancer ( NSCLC ) combination chemotherapy thoracic radiotherapy ( TRT ) . The standard regimen consist platinum-based doublet chemotherapy.Icotinib ( BPI-2009 , Conmana ) first self-developed small molecular drug China target therapy lung cancer.Icotinib novel oral quinazoline compound proven survival benefit Chinese patient lung cancer , especially EGFR mutation lung cancer . This randomised , multi-center , controlled trial design assess efficacy safety icotinib concurrent radiotherapy versus pemetrexed + carboplatin concurrent radiotherapy inoperable stage III non-small cell lung cancer EGFR mutation , primary endpoint progression-free survival .</brief_summary>
	<brief_title>Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Unresectable stage IIIA / IIIB nonsmall cell lung cancer EGFR 19/21 mutation . 2 . No previous systemic anticancer therapy . 3. life expectancy three month . 4 . ECOG Performance Status 0 1 . 5 . Measurable lesion accord RECIST least one measurable lesion previously irradiate , unless disease progression document site . 6 . Patients require provide inform consent enrollment . 1 . Intrapulmonary metastasis , atelectasis entire hemithorax , pleural dissemination , contralateral hilar lymph node metastasis . 2 . Prior chemotherapy NSCLC , chest irradiation therapy , therapy direct epidermal growth factor receptor pathway . 3 . Severe heart disease , uncontrolled diabetes mellitus , active infection . 4 . Active concomitant malignancy , pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Inoperable stage III non-small cell lung cancer</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>Icotinib</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Chemoradiotherapy</keyword>
</DOC>